osteogenesis imperfecta

Pomerantz Law Firm filed class action against $MREO after Phase 3 trial failures. Stock plummeted 87.7%. Investor deadline: April 6, 2026.

Class action suits filed against Ultragenyx and Mereo BioPharma following failed Phase III trials for setrusumab, with stock prices crashing 42.32% and 87.7% respectively.

Class action lawsuit filed against $UGXY alleging securities fraud over misleading setrusumab trial data and OI patient safety disclosures.

Investors in $MREO have until April 6, 2026 to join securities class action alleging misleading statements about failed Phase 3 setrusumab trials.

Ultragenyx faces a securities class action alleging misrepresentations about its setrusumab drug's efficacy for osteogenesis imperfecta. Affected investors have until April 6, 2026 to serve as lead plaintiff.

Global skeletal dysplasia market projected to grow from $3.48B (2026) to $5.37B (2032) at 7.42% CAGR, driven by diagnostic advances and innovative therapies.

Ultragenyx Pharmaceutical faces securities lawsuit after setrusumab trial failure caused 42% stock decline. Lead plaintiff deadline April 6, 2026.

Securities class action filed against $MREO for allegedly misleading investors about Phase 3 clinical trial results. Lead plaintiff deadline April 6, 2026.

Robbins LLP sues Mereo BioPharma over setrusumab trial failures; stock crashes 87.7% to $0.29 after December 29 announcement.

Class action lawsuit filed against $UGDX alleging false statements about setrusumab efficacy for Osteogenesis Imperfecta, claiming Phase III results overstated drug benefits.

Mereo BioPharma faces securities class action for allegedly concealing failed Phase 3 trials for setrusumab. Investors have until April 6, 2026 to act.

Ultragenyx faces securities lawsuit over delayed disclosure of failed Phase 3 trial. Investors must file lead plaintiff claims by April 6, 2026.

Portnoy Law Firm filed securities class action against Ultragenyx Pharmaceutical, alleging the company made false statements about investigational drug setrusumab and concealed material clinical trial risks.

Ultragenyx faces securities lawsuit after failing to disclose setrusumab trial failure, causing 42% stock drop. Investors claim company withheld material information before December announcement.

Ultragenyx faces securities lawsuit alleging false claims about drug setrusumab for bone disease. Investors have until April 6, 2026 deadline to join class action.

Ultragenyx faces class action lawsuit for allegedly misleading investors about setrusumab efficacy and failing to disclose Phase III trial risks adequately.

Class action lawsuits filed against Ultragenyx and Mereo after Phase III clinical trials for setrusumab failed. Stock prices plummeted 42% and 88% respectively following the announcement.

Mereo BioPharma faces securities lawsuit for allegedly making false statements about setrusumab trial results, causing artificially inflated stock prices and investor losses.

Rosen Law Firm sues Ultragenyx for securities fraud, alleging executives misrepresented drug efficacy. Investors who bought stock August 2023-December 2025 can claim damages by April 6, 2026 deadline.

Ultragenyx Pharmaceutical faces class action lawsuit for allegedly making false statements about setrusumab drug efficacy and safety, affecting investors who bought securities between August 2023 and December 2025.